Alopecia areata patients show increased inflammation and OX40 activation, suggesting a new treatment target.
August 2024 in “Drug Design Development and Therapy” Decursin shows promise for treating cancer, neuroprotection, inflammation, and hair loss.
April 2024 in “International journal of molecular sciences” Alopecia areata and vitiligo share immune system dysfunction but differ in specific immune responses and affected areas.
January 2024 in “Inflammation and regeneration” Th22 cells are essential for Tβ15-induced hair growth in mice.
December 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” MCPIP1 in myeloid cells is important for skin cancer development and healthy hair growth.
November 2023 in “Aktualʹnì problemi sučasnoï medicini” The guidelines suggest using various treatments, including antidepressants and steroids, for alopecia areata and discuss the condition's genetic and immune aspects.
July 2023 in “Stem Cells Translational Medicine” Mesenchymal Stem/Stromal Cells (MSCs) help in wound healing and tissue regeneration, but can also contribute to tumor growth. They show promise in treating chronic wounds and certain burns, but their full healing mechanisms and potential challenges need further exploration.
May 2023 in “Journal of Investigative Dermatology” Blocking DPP4 can potentially speed up hair growth and regeneration, especially after injury or in cases of hair loss.
ILC1-like cells can independently cause alopecia areata by affecting hair follicles.
Non-immune dermal cells dominate, epidermal cells increase after day 9, and certain immune cells persist beyond inflammation in wound-induced hair follicle regeneration.
January 2019 in “Springer eBooks” Combination therapies might work better for some vitiligo patients, but results vary.